Broadcast your events with reliable, high-quality live streaming. Analysis and a navigation map of what we have learned so far and what remains unknown.Make social videos in an instant: use custom templates to tell the right story for your business. Development of a rapid point-of-care diagnostic test for COVID-19In other words, as more people become familiar with the concept. If your friend or loved one needs wheelchair assistance or will need it if you are not given an escort pass, call the airline(s) in question at least 48 hours in advance and ask to arrange wheelchair service. Alon Kollmann Facebook Friend Mapper Maulid Ad Diba Doc Elevated Permissions Are Required To Run Dism Kubota Z600 Engine Parts Xsplit Broadcaster Latest Crack Chess Piece Values I Ma Groot Mp3 ×.
Rapid, simple and specific point-of-care diagnostic tests are urgently needed for the quick isolation of those infected. Cases in healthcare workers and other close contacts indicate human-to-human transmission. The outbreak started in the city of Wuhan (China) and then soon turned into a pandemic with over 60,000 clinical cases and at least 1,500 fatalities. This virus is genetically similar to SARS and MERS coronaviruses. Get your team aligned with all the tools you need on one secure, reliable video platform.A novel zoonotic coronavirus (SARS-CoV-2) has recently been identified in patients with an acute and potentially fatal respiratory disease (COVID-19).
In past work on a similar coronavirus from China, Severe Acute Respiratory Virus (SARS) prevalent in 2002-03, our group modified inhibitors for a protein it produces and requires, namely the 3CL protease. This disease, Covid-19, could become a pandemic unless appropriate measures or cures are found. Seven cases have been reported in Canada. The aptamer-based sensors can rapidly ( 44,730 people are infected in China and >1114 have died (97 in a single day). We propose to develop rapid point-of-care tests based on aptamer-assisted graphene oxide (AptaGO) and paper enzyme-linked aptamer assays (p-ELAA) for SARS-CoV-2 and its surrogate (HCoV-229E), which is a Containment Level 2 (CL-2) pathogen.
Alon Kollmann Facebook Friend Mapper Series Of Its
In addition, we propose to clone and express the 3CL protease (non-infectious) of the Wuhan coronavirus (SARS-CoV-2). We propose to make the key compound and a series of its analogs by chemical synthesis. This infection is almost always fatal, but the key compound effected cures or significant remissions in all the cats. Recently, chemical compounds we previously made for the original SARS 3CL inhibition were slightly altered and one new derivative was shown to cure cats of feline infectious peritonitis (FIP), a natural mutant of feline enteric coronavirus (FECV). Of the 306 amino acid residues in the chain that makes the 3CL protease of the "Wuhan" virus (SARS-CoV-2), only 12 are different and they are highly similar in properties. Genome sequencing of the current "Wuhan" virus, SARS-CoV-2, demonstrates that it also has a 3CL protease that is nearly identical (96% the same).
This will help determine which vaccines can be advance for further study. Specifically, the objectives of this proposal include: 1) Isolation of virus and generation of an in vitro reverse-genetics COVID-19 system 2) Identification of neutralizing antibodies 3) Development and evaluation of candidate vaccines Additionally, the project will generate data on the safety of candidate vaccines in humans through a phase I trial. Our proposal seeks to address these areas of need by a multifaceted approach. Currently, there are no vaccines or therapeutics, but these are urgently needed to bring the epidemic under control. Since it was first identified there have been over 69000 cases, and 1600 deaths, and the virus has spread to multiple countries. Often patients require hospitalization and intensive care, which increases the chance of viral spread within health care settings.
This proposal will develop tools that can be shared with the world scientific community that will help further our understanding of viral pathogenesis, transmission as well as screen potential small-molecule inhibitors and antibodies. He has led multinational collaborations in the past, and has a history of promoting collaborative and transparent consortium-based research programs. Kobinger's group has an established track record of translational research, and has successfully brought a DNA-vaccine against MERS-CoV to phase I clinical trials 24 months after commencing the project and in less than 7 months for Zika virus.
The urgent situation is pressing the global community to respond rapidly together to develop a vaccine or small molecule drug to inhibit viral infection. These approaches, mostly based on drug repurposing (new indication for an existing drug), will result in rapid identification of anti-SARS CoV-2 compounds with accelerated clinical development.Augmented Discovery of Potential Inhibitors of SARS-CoV-2 3CL ProteaseThe COVID-19 epidemic is causing serious or even fatal respiratory tract infections around the city of Wuhan, China and other countries. In-depth evaluation of selected compounds will include in vitro, ex vivo (human bronchial epithelium tissues) and in vivo (animal models) studies. This proposal aims at discovering and evaluating active compounds by rational design through 3D modeling of key viral proteins and also by analyzing cellular gene signatures induced by the virus. Development of effective antivirals is a major global priority especially early in the epidemic when vaccines are unavailable.
In addition we will use X-ray crystallography to refine the protease 3D crystal structure to accelerate the development of COVID-19 therapeutic drug development. We will screen these compounds with a high throughput screening biochemical assay and then evaluate these hits using a cell-based SARS-CoV-2 viral replication assay in a Canadian Containment Level 3 facilty at University of British Columbia. We have applied this novel algorithm to identify 1000 quality "candidate" compounds to inhibit the SARS-CoV-2 main protease (3CLpro) which is uniquely critical for the viral life cycle.
The virus has infected over 64,000 people and caused 1380 deaths and the World Health Organization has declared it a public health emergency of international concern. SARS-CoV-2 is responsible for COVID-19, a disease that arose in Wuhan China in December of 2019. This accomplishment coupled with fast tracking anti-viral assays at UBC and high resolution 3D structure characterization provide our team, Canadians and global colleagues an enormous head start on developing an anti-viral therapeutic for COVID-19Neutralizing Antibodies as SARS-CoV-2 TherapeuticsThree highly virulent coronaviruses - SARS-CoV, MERS-CoV and SARS-CoV-2 - have crossed species barriers to infect humans since 2003. Our first application this month of "Deep Docking" enabled the screening of 1.3B commercially available compounds against the essential SARS-CoV-2 protease, in 1 week compared to the 3 years of conventional docking. Our expertise, facilities, and capabilities in cutting-edge Artificial Intelligence, inhibitor modeling, X-ray crystallography, coronavirus protease inhibition, human viral pathogen research, and anti-viral therapeutics are world class.
0 kommentar(er)
